Form 8-K - Current report:
SEC Accession No. 0001628280-24-045807
Filing Date
2024-11-06
Accepted
2024-11-06 17:12:00
Documents
15
Period of Report
2024-11-06
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20241106.htm   iXBRL 8-K 27815
2 EX-99.1 a8kcaldolorstudy5.htm EX-99.1 23312
6 image_0.jpg GRAPHIC 24290
  Complete submission text file 0001628280-24-045807.txt   214408

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20241106.xsd EX-101.SCH 1894
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20241106_lab.xml EX-101.LAB 21900
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20241106_pre.xml EX-101.PRE 12611
17 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20241106_htm.xml XML 2828
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 241432177
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)